euro adhoc: Bayer Schering Pharma AG / Interim Announcement

--------------------------------------------------------------------------------
Intermediate report of the management transmitted by euro adhoc. The issuer
is responsible for the content of this announcement.
--------------------------------------------------------------------------------

28.04.2008

Interim Announcement by Bayer Schering Pharma AG April 28, 2008

Bayer Schering Pharma AG maintains its growth course

On account of the integration of Bayer Schering Pharma AG into the
Bayer Group and the associated changes in legal-entity structure, the
absolute values for the Bayer Schering Pharma AG Group companies and
their segments are no longer comparable with the corresponding
prior-year periods. This data therefore will not be provided. Net
sales of key Bayer Schering Pharma products - including business now
treated as that of other Bayer Group companies - are given in the
Bayer Group Financial Report as of March 31, 2008.

Bayer Schering Pharma posts gratifying operating performance

The principle growth driver in our Women's Healthcare business unit
was the Yasmin®/YAZ®/Yasminelle® family of oral contraceptive
products.

In the Diagnostic Imaging business unit, sales of Ultravist® grew,
although prior-year sales were depressed by temporary interruption of
the distribution of the Ultravist® 370 mgl/ml formulation.

In the Specialized Therapeutics business unit, sales of
Betaferon®/Betaseron® for the treatment of multiple sclerosis (MS)
increased yet again.

Integration of the Bayer Schering Pharma AG Group into the Bayer
Group

With the registration of the domination and profit-and-loss transfer
agreement at the end of October 2006, work started on integrating the
Bayer Schering Pharma AG Group companies into the Bayer Group and
merging the pharmaceuticals business of Bayer Schering Pharma AG and
its subsidiaries with that of the Bayer Group. Both of these
businesses are to be managed uniformly in the interest of the Bayer
Group and its subgroup Bayer HealthCare. All key functional areas,
especially research and development, procurement, production, sales,
marketing and administration, have now been amalgamated.

In the course of integrating the Bayer Schering Pharma AG Group
companies into the Bayer Group, one company was deconsolidated in the
first quarter of 2008 following amalgamation with a Bayer Group
company. In this context, a total of 89 companies were deconsolidated
in 2006 and 2007 following their sale or an exchange of shares.

To facilitate implementation of the necessary restructuring measures,
Bayer Schering GmbH - as the majority stockholder of Bayer Schering
Pharma AG - is seeking the transfer of all shares in Bayer Schering
Pharma AG. Under a resolution adopted by the Extraordinary
Stockholders' Meeting of Bayer Schering Pharma AG on January 17,
2007, Bayer Schering GmbH, a wholly owned subsidiary of Bayer AG and
majority stockholder of Bayer Schering Pharma AG, is to acquire the
shares held by the minority stockholders in return for compensation
in cash of EUR 98.98 per share. Dissenting stockholders are seeking
to have the stockholder resolution set aside or to have it declared
null and void.

Legal risks

To find out more about Bayer Schering Pharma AG's overall risk
situation, please refer to pages 48-55 of the Bayer Schering Pharma
AG Annual Report 2007, which can be downloaded free of charge at
www.schering.de. Since the Bayer Schering Pharma AG Annual Report
2007 was published, the following significant changes have occurred
in respect of the legal risks:

Yasmin®: On page 50 of the Bayer Schering Pharma AG Annual Report
2007, we reported that Bayer Schering Pharma filed a suit against
Barr Pharmaceuticals Inc. and Barr Laboratories Inc. in U.S. federal
court, alleging patent infringement by Barr for the intended generic
version of Bayer Schering Pharma's Yasmin® oral contraceptive product
in the United States. In June 2005, Barr filed its counterclaim
seeking to invalidate Bayer Schering Pharma's patent. In early March
2008, the U.S. federal court invalidated Bayer Schering Pharma AG's
´531 patent for Yasmin®. Bayer Schering Pharma has appealed this
ruling.

In March 2008, Bayer HealthCare Pharmaceuticals Inc. and Bayer
Schering Pharma AG received two notices of an Abbreviated New Drug
Application (ANDA) pursuant to which Watson Laboratories Inc. and
Sandoz Inc. are each seeking approval to market a generic version of
Bayer Schering Pharma's oral contraceptive Yasmin® in the United
States. Bayer Schering Pharma has filed a suit against Watson and
Sandoz in U.S. federal court alleging patent infringement.

YAZ®: On page 50 of the Bayer Schering Pharma AG Annual Report 2007,
we reported that, in January 2007, Barr Laboratories Inc. filed an
ANDA application with the U.S. FDA seeking approval of a generic
version of Bayer Schering Pharma's YAZ® oral contraceptive in the
United States. In October 2007, Bayer Schering Pharma was notified
that Watson Laboratories Inc. had also filed an ANDA application for
a generic version of YAZ® in the United States. Both applications
claim that the Bayer Schering Pharma patents are invalid and/or that
the respective generic product does not infringe them. Bayer Schering
Pharma has filed a patent infringement suit against Watson claiming,
inter alia, that Bayer Schering Pharma's ´531 patent has been
infringed. Bayer Schering Pharma's ´531 patent is also at issue in
the patent infringement suit against Barr, mentioned previously,
involving the oral contraceptive Yasmin®. Bayer Schering Pharma is
currently evaluating the impact of the court's decision regarding
Yasmin® on YAZ®. However, regardless of the outcome of the court's
decision invalidating the company's ´531 patent with regard to
Yasmin®, Bayer Schering Pharma retains marketing exclusivity for YAZ®
as an oral contraceptive in the United States until March 16, 2009.
No generic manufacturer can lawfully market a generic version of YAZ®
for an oral contraceptive indication until after March 16, 2009.

Since mid-March 2007, the shares of Bayer Schering Pharma AG have not
been admitted to the Prime Standard Segment of the Frankfurt Stock
Exchange where there are additional reporting obligations. Since
then, Bayer Schering Pharma AG has not been subject to these
additional reporting obligations, but only to the general reporting
requirements of the German Stock Exchange Admission Regulations and
the provisions of the German Securities Trading Act (WpHG). Effective
since 2007, the WpHG obligates listed companies to publish interim
announcements by the Board of Management twice a year. The American
Depositary Receipts (ADRs) of Bayer Schering Pharma AG have not been
traded on the New York Stock Exchange since November 2006. In
addition, the registration of Bayer Schering Pharma AG shares with
the U.S. Securities and Exchange Commission ended as of September 2,
2007. Bayer Schering Pharma AG is therefore no longer subject to the
obligations in connection with the registration as demanded by U.S.
stock corporation laws including the Sarbanes-Oxley Act of 2002. In
particular, Bayer Schering Pharma AG will no longer publish Annual
Reports on Form 20-F. The secondary listing of Bayer Schering Pharma
AG on the SWX Swiss Exchange was revoked as of December 28, 2007. The
bearer shares of Bayer Schering Pharma AG will continue to be listed
on the Frankfurt Stock Exchange.

Berlin, April 28, 2008

Bayer Schering Pharma Aktiengesellschaft
The Board of Management

Forward-Looking Statements This Interim Announcement contains
forward-looking statements based on current assumptions and forecasts
made by Bayer Group management and Bayer Schering Pharma AG
management. Various known and unknown risks, uncertainties and other
factors could lead to material differences between the actual future
results, financial situation, development or performance of the
company and the estimates given here. These factors include those
discussed in our public reports filed with the Frankfurt Stock
Exchange and with the U.S. Securities and Exchange Commission
(including our Form 20-F). The company assumes no liability
whatsoever to update these forward-looking statements or to conform
them to future events or developments.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Bayer Schering Pharma AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Branche: Pharmaceuticals
ISIN: DE0007172009
WKN: 717200
Börsen: Börse Berlin / regulated dealing
Börse Stuttgart / regulated dealing
Börse Düsseldorf / regulated dealing
Börse Hannover / regulated dealing
Börse München / regulated dealing
Börse Frankfurt / regulated dealing/general standard